Table 4.
Treatment effects on FEV1 at week 24 – NMA results: combining direct and indirect evidence (lower triangle) and direct evidence (upper triangle)
| NMA results (combining direct and indirect estimates) | Direct evidence | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Placebo | NA | −137.07 (−169.35, −104.78) |
−79.41 (−101.99, −56.83) |
−161.00 (−223.72, −98.28) |
−128.66 (−207.25, −50.07) |
−159.39 (−187.78, −131.00) |
NA | −185.39 (−228.68, −142.09) |
−138.87 (−156.97, −120.77) |
−115.00 (−154.20, −75.80) |
−125.22 (−142.65, −107.79) |
−115.24 (−131.16, −99.32) |
−114.43 (−134.93, −93.93) |
−120.41 (−133.99, −106.83) |
|
| 48.56 (−3.08, 100.19) |
Ipra | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | −161.20 (−200.40, −122.00) |
|
| −137.27 (−174.32, −100.21) |
−185.82 (−249.39, −122.26) |
FFVI | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| −79.45 (−111.25, −47.66) |
−128.01 (−188.65, −67.37) |
57.81 (8.98, 106.64) |
BudeForm | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| −161.00 (−231.13, −90.87) |
−209.56 (−296.65, −122.46) |
−23.73 (−103.06, 55.59) |
−81.55 (−158.55, −4.54) |
SFC250 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| −95.54 (−117.97, −73.11) |
−144.09 (−199.91, −88.28) |
41.73 (−1.58, 85.03) |
−16.08 (−54.99, 22.83) |
65.46 (−8.17, 139.10) |
SFC500 | NA | NA | −86.15 (−98.06, −74.24) |
NA | NA | NA | NA | NA | NA | |
| −185.89 (−210.29, −161.49) |
−234.45 (−289.94, −178.95) |
−48.62 (−93.00, −4.24) |
−106.44 (−146.52, −66.36) |
−24.89 (−99.15, 49.37) |
−90.35 (−123.15, −57.56) |
UmecVil | NA | NA | NA |
52.00 (16.72, 87.28) |
NA | NA | NA |
92.02 (61.25, 122.78) |
|
| −166.97 (−208.69, −125.25) |
−215.53 (−281.26, −149.80) |
−29.71 (−85.52, 26.11) |
−87.52 (−139.98, −35.06) |
−5.97 (−87.58, 75.64) |
−71.44 (−118.97, −23.90) |
18.92 (−28.77, 66.61) |
TioOlo | NA | NA | NA | NA | NA |
60.00 (42.36, 77.64) |
NA | |
| −182.82 (−203.61, −162.03) |
−231.37 (−285.98, −176.77) |
−45.55 (−88.05, −3.06) |
−103.37 (−141.36, −65.37) |
−21.82 (−94.97, 51.33) |
−87.28 (−107.78, −66.78) |
3.07 (−27.91, 34.05) |
−15.85 (−62.17, 30.48) |
IndaGlyco | NA | NA |
86.15 (68.77, 103.54) |
NA | NA |
76.09 (57.73, 94.46) |
|
| −139.37 (−167.96, −110.78) |
−187.92 (−246.93, −128.91) |
−2.10 (−48.91, 44.70) |
−59.91 (−102.67, −17.15) |
21.63 (−54.11, 97.37) |
−43.83 (−80.21, −7.45) |
46.52 (8.96, 84.08) |
27.60 (−22.94, 78.15) |
43.45 (8.10, 78.80) |
AclForm | NA | NA |
26.94 (2.72, 51.17) |
NA | NA | |
| −125.54 (−169.40, −81.68) |
−174.10 (−241.08, −107.11) |
11.73 (−45.70, 69.15) |
−46.09 (−100.26, 8.09) |
35.46 (−47.26, 118.18) |
−30.00 (−79.17, 19.16) |
60.35 (17.31, 103.39) |
41.43 (−18.78, 101.65) |
57.28 (9.13, 105.42) |
13.83 (−38.51, 66.17) |
Umec | NA | NA | NA | NA | |
| −119.24 (−138.18, −100.30) |
−167.79 (−221.71, −113.88) |
18.03 (−23.58, 59.64) |
−39.78 (−76.79, −2.78) |
41.76 (−30.88, 114.41) |
−23.70 (−50.33, 2.93) |
66.65 (36.86, 96.44) |
47.73 (2.13, 93.34) |
63.58 (40.20, 86.96) |
20.13 (−14.18, 54.44) |
6.30 (−41.09, 53.69) |
Glyco | NA | NA | 8.18 (−26.31, 42.67) |
|
| −115.15 (−140.60, −89.70) |
−163.71 (−221.26, −106.15) |
22.12 (−22.84, 67.07) |
−35.70 (−76.42, 5.03) |
45.85 (−28.76, 120.46) |
−19.61 (−53.56, 14.33) |
70.74 (35.50, 105.98) |
51.82 (2.97, 100.67) |
67.67 (34.81, 100.53) |
24.22 (−7.41, 55.85) |
10.39 (−40.31, 61.09) |
4.09 (−27.64, 35.82) |
Acl | NA | NA | |
| −108.33 (−129.58, −87.07) |
−156.88 (−211.98, −101.78) |
28.94 (−13.79, 71.67) |
−28.87 (−67.12, 9.37) |
52.67 (−20.61, 125.96) |
−12.79 (−43.78, 18.20) |
77.57 (46.08, 109.05) |
58.65 (22.70, 94.59) |
74.49 (45.23, 103.76) |
31.04 (−4.55, 66.63) |
17.21 (−31.17, 65.60) |
10.91 (−17.15, 38.98) |
6.82 (−26.30, 39.95) |
Tio5 | NA | |
| −114.07 (−126.34, −101.80) |
−162.63 (−212.80, −112.45) |
23.20 (−15.84, 62.23) |
−34.62 (−68.70, −0.54) |
46.93 (−24.27, 118.13) |
−18.53 (−42.79, 5.72) |
71.82 (47.97, 95.68) |
52.90 (10.29, 95.52) |
68.75 (47.19, 90.30) |
25.30 (−5.80, 56.40) |
11.47 (−32.97, 55.91) |
5.17 (−14.50, 24.84) |
1.08 (−27.16, 29.32) |
−5.74 (−28.72, 17.23) |
Tio18 | |
Notes: Comparisons between treatments should be read from left to right. The MD in milliliters with 95% CI are shown in the cell. MD >0 favors the column-defining treatment (lower triangle) and the row-defining treatment (upper triangle). Statistically significant results in bold.
Abbreviations: Acl, aclidinium; AclForm, aclidinium/formoterol; BudeForm, budesonide/formoterol; FFVI, fluticasone/vilanterol; Glyco, glycopyrronium; IndaGlyco, indacaterol/glycopyrronium; Ipra, ipratropium; MD, mean difference; NA, results not available; NMA, network meta-analysis; SFC250, fluticasone/salmeterol 250/50 mcg; SFC500, fluticasone/salmeterol 500/50 mcg; Tio5, tiotropium 5 mcg; Tio18, tiotropium 18 mcg; TioOlo, tiotropium/olodaterol; Umec, umeclidinium; UmecVil, umeclidinium/vilanterol.